The Synergistic Effect of Fotemustine and Genistein on Expressions of p53, EGFR and COX-2 Genes in Human Glioblastoma Multiforme Cell Line
Küçük Resim Yok
Tarih
2012
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
GBM yetişkinlerde merkezi sinir sisteminin en yaygın primer malin neoplazmıdır. Fotemustin (FTM) sitotoksik bir ajan ve lifofilik kloroetilnitrozüri türevidir. DNA zincir kırıklarını ve çapraz bağlanmayı indüklemek ana mekanizmasını oluşturmaktadır. Soyadan elde edilen bir isoflavon olan Genistein, antikanser özelliğini tirozin fosforilasyonunun inhibisyonu, zayıf östrojenik ve anti-östrojenik özellikleri, antioksidan olarak, topoizomeraz II' nin inhibisyonu, anjiyogenezin inhibisyonu ve hücre faklılaşmasının başlaması gibi çeşitli mekanizmalar ile göstermektedir. Genisteinin fotemustin ile anti-proliferatif sinerjistik etkisinin insan glioblastoma multiforme U87-MG hücrelerinde incelenmesi amaçlanmıştır. Bu çalışma ayrıca p53, EGFR, COX-2 gen ekspresyon paternlerinin bu ilaçların ayrı ayrı veya kombine kullanılmasının ardından faklılık gösterip göstermediğine cevap verebilmek için tasarlanmıştır.
GBM is the most common primary malignant neoplasm of the central nervous system in adults. Fotemustine (FTM) is a cytotoxic alkylating agent and a lipophilic chloroethylnitrosourea derivative. Its mechanism of action consists mainly in inducing DNA strand breaks and cross-linking. Genistein, one of the soy-derived isoflavones, exerts its anticancer properties via several mechanisms, including inhibition of tyrosine phosphorylation, weak estrogenic and anti-estrogenic properties, as an antioxidant, inhibition of topoisomerase II, inhibition of angiogenesis, and induction of cell differentiation in a number of human tumors. We aimed to investigate the anti-proliferative synergistic effect of genistein with fotemustine on human glioblastoma multiforme U87-MG cells. This study was also designed to answer the following question: Do the p53, EGFR, COX-2 genes' expression patterns differ in treatment of these both drugs alone and in combination?
GBM is the most common primary malignant neoplasm of the central nervous system in adults. Fotemustine (FTM) is a cytotoxic alkylating agent and a lipophilic chloroethylnitrosourea derivative. Its mechanism of action consists mainly in inducing DNA strand breaks and cross-linking. Genistein, one of the soy-derived isoflavones, exerts its anticancer properties via several mechanisms, including inhibition of tyrosine phosphorylation, weak estrogenic and anti-estrogenic properties, as an antioxidant, inhibition of topoisomerase II, inhibition of angiogenesis, and induction of cell differentiation in a number of human tumors. We aimed to investigate the anti-proliferative synergistic effect of genistein with fotemustine on human glioblastoma multiforme U87-MG cells. This study was also designed to answer the following question: Do the p53, EGFR, COX-2 genes' expression patterns differ in treatment of these both drugs alone and in combination?
Açıklama
Anahtar Kelimeler
Nörolojik Bilimler
Kaynak
Journal of Neurological Sciences (Turkish)
WoS Q Değeri
Scopus Q Değeri
Cilt
29
Sayı
3
